Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias

Carlo Napolitano, Peter J. Schwartz, Arthur M. Brown, Elena Ronchetti, Laura Bianchi, Aldo Pinnavaia, Giovanni Acquaro, Silvia G. Priori

Research output: Contribution to journalArticle

263 Citations (Scopus)

Abstract

The aim of this study was to test the hypothesis that some cases of drug-induced arrhythmias depend on genetic predisposition. Excessive prolongation of the QT interval and life-threatening arrhythmias (torsades de pointes or ventricular fibrillation) may occur in response to a variety of cardiac and noncardiac drugs, with detrimental effects on patient safety and the investments made by the pharmaceutical industry. Moss and Schwartz hypothesized that some drug-induced arrhythmias might represent cases of 'forme fruste' of the congenital long QT syndrome (LQTS). The availability of molecular screening techniques for LQTS genes allowed us to test this hypothesis. An elderly female patient with documented cardiac arrest related to cisapride, a prokynetic drug that blocks I(Kr), and transiently prolonged QT interval underwent mutational analysis of the known LQTS-related genes performed by single-strand conformational polymorphism and DNA sequencing. Double-electrode voltage clamp in Xenopus oocytes as the expression system was used to study the in vitro cellular phenotype caused by the genetic defect in coexpression with the wild-type (WT) gene. Molecular analysis revealed a heterozygous mutation leading to substitution of a highly conserved amino acid in the pore region of KvLQT1. This mutation was present not only in the patient with ventricular fibrillation but also in her two adult asymptomatic sons who have a normal QT interval. In vitro expression of the mutated KvLQT1 protein showed a severe loss of current with a dominant negative effect on the WT-KvLQT1 channel. Our findings demonstrate that some cases of drug-induced QT prolongation may depend on a genetic substrate. Molecular screening may allow identification among family members of gene carriers potentially at risk if treated with I(Kr) blockers. Evolving technology may lead to rapid screening for mutations of candidate genes that cause drug-induced life-threatening arrhythmias and allow early identification of individuals at risk.

Original languageEnglish
Pages (from-to)691-696
Number of pages6
JournalJournal of Cardiovascular Electrophysiology
Volume11
Issue number6
Publication statusPublished - 2000

Fingerprint

Life Support Care
Ion Channels
Cardiac Arrhythmias
Long QT Syndrome
Mutation
Pharmaceutical Preparations
Genes
Ventricular Fibrillation
Cisapride
Bryophyta
Torsades de Pointes
Drug Industry
Adult Children
Genetic Predisposition to Disease
Patient Safety
Xenopus
Heart Arrest
DNA Sequence Analysis
Oocytes
Electrodes

Keywords

  • Acquired long QT syndrome
  • Drug-induced arrhythmias
  • Genetics
  • Sudden cardiac death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. / Napolitano, Carlo; Schwartz, Peter J.; Brown, Arthur M.; Ronchetti, Elena; Bianchi, Laura; Pinnavaia, Aldo; Acquaro, Giovanni; Priori, Silvia G.

In: Journal of Cardiovascular Electrophysiology, Vol. 11, No. 6, 2000, p. 691-696.

Research output: Contribution to journalArticle

@article{2ad1a3c832004bb1ab9b3dc2a4f590a9,
title = "Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias",
abstract = "The aim of this study was to test the hypothesis that some cases of drug-induced arrhythmias depend on genetic predisposition. Excessive prolongation of the QT interval and life-threatening arrhythmias (torsades de pointes or ventricular fibrillation) may occur in response to a variety of cardiac and noncardiac drugs, with detrimental effects on patient safety and the investments made by the pharmaceutical industry. Moss and Schwartz hypothesized that some drug-induced arrhythmias might represent cases of 'forme fruste' of the congenital long QT syndrome (LQTS). The availability of molecular screening techniques for LQTS genes allowed us to test this hypothesis. An elderly female patient with documented cardiac arrest related to cisapride, a prokynetic drug that blocks I(Kr), and transiently prolonged QT interval underwent mutational analysis of the known LQTS-related genes performed by single-strand conformational polymorphism and DNA sequencing. Double-electrode voltage clamp in Xenopus oocytes as the expression system was used to study the in vitro cellular phenotype caused by the genetic defect in coexpression with the wild-type (WT) gene. Molecular analysis revealed a heterozygous mutation leading to substitution of a highly conserved amino acid in the pore region of KvLQT1. This mutation was present not only in the patient with ventricular fibrillation but also in her two adult asymptomatic sons who have a normal QT interval. In vitro expression of the mutated KvLQT1 protein showed a severe loss of current with a dominant negative effect on the WT-KvLQT1 channel. Our findings demonstrate that some cases of drug-induced QT prolongation may depend on a genetic substrate. Molecular screening may allow identification among family members of gene carriers potentially at risk if treated with I(Kr) blockers. Evolving technology may lead to rapid screening for mutations of candidate genes that cause drug-induced life-threatening arrhythmias and allow early identification of individuals at risk.",
keywords = "Acquired long QT syndrome, Drug-induced arrhythmias, Genetics, Sudden cardiac death",
author = "Carlo Napolitano and Schwartz, {Peter J.} and Brown, {Arthur M.} and Elena Ronchetti and Laura Bianchi and Aldo Pinnavaia and Giovanni Acquaro and Priori, {Silvia G.}",
year = "2000",
language = "English",
volume = "11",
pages = "691--696",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias

AU - Napolitano, Carlo

AU - Schwartz, Peter J.

AU - Brown, Arthur M.

AU - Ronchetti, Elena

AU - Bianchi, Laura

AU - Pinnavaia, Aldo

AU - Acquaro, Giovanni

AU - Priori, Silvia G.

PY - 2000

Y1 - 2000

N2 - The aim of this study was to test the hypothesis that some cases of drug-induced arrhythmias depend on genetic predisposition. Excessive prolongation of the QT interval and life-threatening arrhythmias (torsades de pointes or ventricular fibrillation) may occur in response to a variety of cardiac and noncardiac drugs, with detrimental effects on patient safety and the investments made by the pharmaceutical industry. Moss and Schwartz hypothesized that some drug-induced arrhythmias might represent cases of 'forme fruste' of the congenital long QT syndrome (LQTS). The availability of molecular screening techniques for LQTS genes allowed us to test this hypothesis. An elderly female patient with documented cardiac arrest related to cisapride, a prokynetic drug that blocks I(Kr), and transiently prolonged QT interval underwent mutational analysis of the known LQTS-related genes performed by single-strand conformational polymorphism and DNA sequencing. Double-electrode voltage clamp in Xenopus oocytes as the expression system was used to study the in vitro cellular phenotype caused by the genetic defect in coexpression with the wild-type (WT) gene. Molecular analysis revealed a heterozygous mutation leading to substitution of a highly conserved amino acid in the pore region of KvLQT1. This mutation was present not only in the patient with ventricular fibrillation but also in her two adult asymptomatic sons who have a normal QT interval. In vitro expression of the mutated KvLQT1 protein showed a severe loss of current with a dominant negative effect on the WT-KvLQT1 channel. Our findings demonstrate that some cases of drug-induced QT prolongation may depend on a genetic substrate. Molecular screening may allow identification among family members of gene carriers potentially at risk if treated with I(Kr) blockers. Evolving technology may lead to rapid screening for mutations of candidate genes that cause drug-induced life-threatening arrhythmias and allow early identification of individuals at risk.

AB - The aim of this study was to test the hypothesis that some cases of drug-induced arrhythmias depend on genetic predisposition. Excessive prolongation of the QT interval and life-threatening arrhythmias (torsades de pointes or ventricular fibrillation) may occur in response to a variety of cardiac and noncardiac drugs, with detrimental effects on patient safety and the investments made by the pharmaceutical industry. Moss and Schwartz hypothesized that some drug-induced arrhythmias might represent cases of 'forme fruste' of the congenital long QT syndrome (LQTS). The availability of molecular screening techniques for LQTS genes allowed us to test this hypothesis. An elderly female patient with documented cardiac arrest related to cisapride, a prokynetic drug that blocks I(Kr), and transiently prolonged QT interval underwent mutational analysis of the known LQTS-related genes performed by single-strand conformational polymorphism and DNA sequencing. Double-electrode voltage clamp in Xenopus oocytes as the expression system was used to study the in vitro cellular phenotype caused by the genetic defect in coexpression with the wild-type (WT) gene. Molecular analysis revealed a heterozygous mutation leading to substitution of a highly conserved amino acid in the pore region of KvLQT1. This mutation was present not only in the patient with ventricular fibrillation but also in her two adult asymptomatic sons who have a normal QT interval. In vitro expression of the mutated KvLQT1 protein showed a severe loss of current with a dominant negative effect on the WT-KvLQT1 channel. Our findings demonstrate that some cases of drug-induced QT prolongation may depend on a genetic substrate. Molecular screening may allow identification among family members of gene carriers potentially at risk if treated with I(Kr) blockers. Evolving technology may lead to rapid screening for mutations of candidate genes that cause drug-induced life-threatening arrhythmias and allow early identification of individuals at risk.

KW - Acquired long QT syndrome

KW - Drug-induced arrhythmias

KW - Genetics

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=0034083759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034083759&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 691

EP - 696

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 6

ER -